AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
企業コードRCEL
会社名AVITA Medical Inc
上場日Mar 18, 2012
最高経営責任者「CEO」Mr. James M. (Jim) Corbett
従業員数260
証券種類Ordinary Share
決算期末Mar 18
本社所在地28159 Avenue Stanford
都市VALENCIA
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号91355
電話番号16613679170
ウェブサイトhttps://www.avitamedical.com/
企業コードRCEL
上場日Mar 18, 2012
最高経営責任者「CEO」Mr. James M. (Jim) Corbett
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし